CSE:AIAI - Post Discussion
Post by
partystocker on Feb 22, 2022 12:10pm
$MEND.C Seeks Pivotal Role In The $94B CNS Industry
This week is going to be pivotal for the share price of Nurosene (CSE: MEND) as the company’s stock retests resistance at $.745, on a bounce from near all-time lows. Shares are currently up 48% from January’s low point of $.505.
$MEND.C recently launched NetraPlacebo, the company’s AI-driven solution to aid the $94B CNS industry in preventing clinical trial failure. CNS trials currently have a success rate of only 15%, so if this solution is proven successful there is a huge opportunity for $MEND.C in this market.
Earlier research done by $MEND on placebo response was able to identify a greater proportion of potential placebo respondents even in those with lower levels of disease severity, allowing for more confidence when trying to establish a true signal of efficacy. Further research used to create and validate the NetraPlacebo technology was recently completed with a top pharmaceutical company and will be published shortly.
Shares of $MEND.C are currently trading at $.75 and the company is valued at a market cap of $30.1 million.
https://ceo.ca/@newswire/nurosene-launches-netraplacebo-an-innovative-ai-technology
Be the first to comment on this post